140 related articles for article (PubMed ID: 34655175)
1. Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.
Arai H; Inoue E; Yamaguchi K; Boku N; Hara H; Nishina T; Tsuda M; Shitara K; Shinozaki K; Nakamura S; Hyodo I; Muro K; Sasako M; Terashima M; Nakajima TE
Cancer Med; 2021 Nov; 10(21):7673-7682. PubMed ID: 34655175
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G).
Nakajima TE; Yamaguchi K; Boku N; Hyodo I; Mizusawa J; Hara H; Nishina T; Sakamoto T; Shitara K; Shinozaki K; Katayama H; Nakamura S; Muro K; Terashima M
Gastric Cancer; 2020 Jul; 23(4):677-688. PubMed ID: 32036492
[TBL] [Abstract][Full Text] [Related]
3. Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
Iwasa S; Goto M; Yasui H; Nishina T; Takahari D; Nakayama N; Taira K; Kusaba H; Fuse N; Hironaka S; Shimada Y; Nakajima TE
Jpn J Clin Oncol; 2012 Sep; 42(9):787-93. PubMed ID: 22782960
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
[TBL] [Abstract][Full Text] [Related]
6. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W
Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738
[TBL] [Abstract][Full Text] [Related]
7. Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
Arai H; Iwasa S; Boku N; Kawahira M; Yasui H; Masuishi T; Muro K; Minashi K; Hironaka S; Fukuda N; Takahari D; Nakajima TE
BMC Cancer; 2019 Jul; 19(1):652. PubMed ID: 31269916
[TBL] [Abstract][Full Text] [Related]
8. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer.
Matsubara J; Shimada Y; Kato K; Nagai Y; Iwasa S; Nakajima TE; Hamaguchi T; Yamada Y; Takagi S; Kobayashi K; Yoshioka A; Nakayama N; Tsuji A
Oncology; 2011; 81(5-6):291-7. PubMed ID: 22134040
[TBL] [Abstract][Full Text] [Related]
10. WJOG10517G: a multicenter Phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases.
Masuishi T; Nakajima TE; Yamazaki K; Hironaka S; Kudo C; Yoshimura K; Muro K
Future Oncol; 2020 Jul; 16(20):1417-1424. PubMed ID: 32466683
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapeutic Strategies for Peritoneal Dissemination of Gastric Cancer].
Matsushima T; Wakatsuki T; Takahari D; Chin K; Yamaguchi K
Gan To Kagaku Ryoho; 2016 Dec; 43(13):2477-2480. PubMed ID: 28028252
[TBL] [Abstract][Full Text] [Related]
12. First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake.
Hara H; Kadowaki S; Asayama M; Ooki A; Yamada T; Yoshii T; Yamaguchi K
Int J Clin Oncol; 2018 Apr; 23(2):275-280. PubMed ID: 29039072
[TBL] [Abstract][Full Text] [Related]
13. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Kitayama J; Ishigami H; Yamaguchi H; Yamashita H; Emoto S; Kaisaki S; Watanabe T
Ann Surg Oncol; 2014 Feb; 21(2):539-46. PubMed ID: 23975319
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
[TBL] [Abstract][Full Text] [Related]
15. First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer.
Iwasa S; Nakajima TE; Nakamura K; Takashima A; Kato K; Hamaguchi T; Yamada Y; Shimada Y
Gastric Cancer; 2012 Jan; 15(1):21-6. PubMed ID: 21573919
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel in Advanced Gastric Cancer].
Kawada J; Nishino M; Hosoda Y; Hoshino H; Okano M; Nagai K; Okuyama M; Kim Y; Tsujinaka T
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1951-1953. PubMed ID: 28133186
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
Yamaguchi H; Kitayama J; Ishigami H; Emoto S; Yamashita H; Watanabe T
Cancer; 2013 Sep; 119(18):3354-8. PubMed ID: 23798046
[TBL] [Abstract][Full Text] [Related]
18. [A case of advanced gastric cancer with peritoneal metastasis that responded to paclitaxel plus 5-FU therapy].
Kobayashi D; Honda I; Kato T; Mori M
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1313-6. PubMed ID: 16969032
[TBL] [Abstract][Full Text] [Related]
19. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y
Oncology; 2020; 98(1):48-52. PubMed ID: 31487733
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]